深度MRD分析定义标准和高危骨髓瘤的结局并揭示不同的治疗耐药模式
本研究纳入PETHEMA/GEM2012MENOS65试验中300例标危和90例高危细胞遗传学异常的多发性骨髓瘤患者,用二代流式评估可测量残留病(MRD)。标危和高危患者达到MRD不可检测时36个月无进展生存率均高于90%;MRD持续存在时中位无进展生存分别约3年和2年。对40例患者MRD克隆行全外显子组和RNA测序,发现高危骨髓瘤存在活性氧介导的MRD耐药。
要点
- 标危和高危细胞遗传学异常的多发性骨髓瘤患者达到MRD不可检测时36个月无进展生存率均高于90%。
- MRD持续存在时,标危和高危患者中位无进展生存分别约3年和2年。
- 高危骨髓瘤MRD耐药与活性氧介导机制相关,无统一驱动基因事件。
核心结论
- 研究支持将MRD不可检测作为高危细胞遗传学异常多发性骨髓瘤患者的治疗终点,并提出通过表征MRD克隆来理解和克服MRD耐药。
研究设计与样本
- 研究纳入PETHEMA/GEM2012MENOS65试验中300例标危和90例高危细胞遗传学异常的多发性骨髓瘤患者,用二代流式评估MRD,并对40例患者分离MRD后行全外显子组和RNA测序。
主要发现
- 标危和高危细胞遗传学异常患者达到MRD不可检测时36个月无进展生存率均高于90%。
- MRD持续存在时,标危和高危患者中位无进展生存分别约3年和2年。
- 全外显子组测序显示标危患者克隆选择更明显,高危骨髓瘤基因组不稳定性更高并获得新突变,无统一驱动MRD耐药的遗传事件。
- RNA测序显示高危骨髓瘤中MRD克隆被选择具有独特转录程序,并存在活性氧介导的MRD耐药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior progression-free survival (PFS). This questions the legitimacy of CR as a treatment endpoint and represents a biological conundrum regarding the nature of tumor reservoirs that persist after therapy in high-risk MM. We used next-generation flow (NGF) cytometry to evaluate measurable residual disease (MRD) in MM patients with standard- vs high-risk CAs (n = 300 and 90, respectively) enrolled in the PETHEMA/GEM2012MENOS65 trial, and to identify mechanisms that determine MRD resistance in both patient subgroups (n = 40). The 36-month PFS rates were higher than 90% in patients with standard- or high-risk CAs achieving undetectable MRD. Persistent MRD resulted in a median PFS of ∼3 and 2 years in patients with standard- and high-risk CAs, respectively. Further use of NGF to isolate MRD, followed by whole-exome sequencing of paired diagnostic and MRD tumor cells, revealed greater clonal selection in patients with standard-risk CAs, higher genomic instability with acquisition of new mutations in high-risk MM, and no unifying genetic event driving MRD resistance. Conversely, RNA sequencing of diagnostic and MRD tumor cells uncovered the selection of MRD clones with singular transcriptional programs and reactive oxygen species-mediated MRD resistance in high-risk MM. Our study supports undetectable MRD as a treatment endpoint for patients with MM who have high-risk CAs and proposes characterizing MRD clones to understand and overcome MRD resistance. This trial is registered at www.clinicaltrials.gov as #NCT01916252.
引用
- Goicoechea I, Puig N, Cedena MT, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021. PMID: 32693406. doi:10.1182/blood.2020006731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。